Olaparib Plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
December 19, 2019
Will the addition of olaparib to bevacizumab frontline maintenance improve PFS in an unselected population of advanced ovarian cancer patients?
Placebo PO BID
bevacizumab 15mg/kg q3w for 15 months
Olaparib 300mg PO BID
bevacizumab 15mg/kg q3w for 15 months
PFS
High-grade serous or endometrioid ovarian cancer
Primary treatment with bevacizumab resulting in NED, CR, or PR.
Delays due to hematologic toxicity during primary treatment.
Olaparib + Bev vs Placebo + Bev:
median PFS, all: 22.1 vs. 16.6 (SS)
median PFS, BRCAm: 37.2 vs. 21.7 (SS)
median PFS, HRD: 28.1 vs. 16.6 (SS)
median PFS, HR proficient/unknown:16.9 vs. 16.0 (NS)
Anemia, fatigue, nausea more common in olaparib arm.
Grade 3 HTN: 19% vs 30%
Discontinuation 20% vs. 6%
Olaparib added to frontline bevacizumab maintenance prolonged PFS in unselected cohort of patients with advanced ovarian cancer. Greatest benefit seem in BRCAm or HRD patients.